David Meek

David Meek has served as a member of our board since June 2018. Mr. Meek has 30 years of experience in the pharmaceutical industry, where he has held various global executive positions in major pharmaceutical and biotechnology companies. Mr. Meek was appointed CEO of Mirati Therapeutics, a clinical stage oncology biotech company, in September 2021. Prior to this, Mr. Meek served as CEO of FerGene, a gene therapy biotech company focused on cancer. He has also served as CEO of Ipsen and as Executive Vice President and President of the oncology division of Baxalta. Mr. Meek also served as Chief Commercial Officer for Endocyte, an oncology biotech, and spent eight years at Novartis as a global franchise head, CEO of Novartis Canada, and region head of oncology for northern, central and Eastern Europe. Earlier in his career, Mr. Meek spent 14 years at Johnson & Johnson and Janssen Pharmaceutica, where he held a variety of senior U.S. sales and marketing positions. Mr. Meek serves as chairman of the board for Entasis Therapeutics. He holds a B.A. in Management from the University of Cincinnati.